WHAT, IF ANY, ARE THE ETHICAL
OBLIGATIONS OF THE U.S. PATENT OFFICE?
A CLOSER LOOK AT THE BIOLOGICAL
SAMPLING OF INDIGENOUS GROUPS
MARINA L. WHELAN 1

ABSTRACT
The patenting of biological resources collected from
indigenous groups has become a controversial trend. Two U.S.
patents in particular, one claiming a cell-line from a 26-year old
Guayami woman and one claiming a leukemia virus from a
Hagahai man in Papua New Guinea, demonstrate just how volatile
this issue has become. This iBrief examines how, in light of such
“ethically questionable” patents, the U.S. Patent Office has failed
to implement any procedures to identify or curb patent applications
involving indigenous peoples.

INTRODUCTION
¶1
The ethical debate surrounding the patenting of biological material
has reached new levels now that scientists and researchers have been
gathering and patenting DNA samples from indigenous populations around
the world. The debate raises numerous issues. For instance, will the data,
which to date has revealed information on diseases such as leukemia and
AIDS, stigmatize or create outsider prejudice towards indigenous
populations? Have these isolated groups, which may speak different
languages than researchers and scientists, given informed consent to the
researchers and scientists? Should indigenous populations receive
compensation for use of their genetic material? To what extent do these
groups control or own their genetic material, which to many groups holds
very sacred and religious significance? Finally, what are the collective
rights of the tribe, which often defiantly oppose the testing, versus the rights
of individual tribe members who wish to partake in the biological research?

Part I of this iBrief addresses the various aspects of the debate
concerning the biological testing of indigenous peoples and subsequent
¶2
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patenting of test results. Part II of the iBrief will then discuss the Guayami
and Hagahai patents, which have largely fueled this debate. Finally, the last
part of the paper will focus on a much narrower and often overlooked issue.
That is, what are the responsibilities of the U.S. Patent and Trademark
Office (USPTO) to monitor these ethically questionable patent applications?

I. THE DEBATE
The rush to patent genome sequences 2 did not start with the DNA
testing of indigenous peoples. Nor is the public unease with this sort of
intellectual property new. In fact, as early as 1980, the U.S. Supreme Court
declared that the patenting of living micro-organisms was permissible under
U.S. patent laws. 3 There has been a surge in what some scholars have
referred to as “hyperownership,” a term that refers to the international
movement to “own or control access to the subcellular genetic sequences
that direct the structure and characteristics of all living things, or, in popular
usage, nature’s or God’s blueprints for life.” 4 The U.S. has been the leader
in this trend, “extending patent protection to a wide and increasing array of
genetic material.” 5 By the middle of the year 2000, “the [USPTO] had
issued over six thousand patents on full-length genes isolated from living
organisms and were considering over twenty thousand gene-related patent
applications.” 6
¶3

¶4
The legal world has recently addressed human genome sequences
as a source of intellectual property. Debate has arisen regarding whether
doctors have a right to the research and subsequent patenting of a patient’s

2

See, e.g., Brian Gargano, The Quagmire of DNA Patents: Are DNA Sequences
More than Chemical Compositions of Matter?, 2005 SYRACUSE SCI. & TECH. L.
REP. 3, 5 (2005) (“With the advent of recombinant DNA technology and
advanced techniques in DNA sequencing, it became possible to identify and
isolate individual genes. . . . A ‘genome’ is the set of all DNA and DNA
sequences in an organism, including its genes.”), available at
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3
Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (allowing Ananda
Chakrabarty to patent his creation of a genetically engineered bacterium capable
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4
Sabrina Safrin, Hyperownership in a Time of Biotechnological Promise: The
International Conflict to Control the Building Blocks of Life, 98 AM. J. INT’L L.
641, 641 (2004) (addressing how the U.S. and various members of the
international community have approached the “ownership” of biological
material in different ways, with some countries, such as the U.S., utilizing a
patent-based “privatization” system and others maintaining sovereign-based
systems of ownership).
5
Id.
6
Id.
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“discarded” biological tissue. 7 Also, a huge uproar ensued when it was
discovered that research physicians patented and commercialized a test for
Canavan’s disease from the bequeathed biological material of patients who
donated their biological tissue under the belief that it would be used solely
to help diseased patients. 8 Critics have noted that “[p]atient lawsuits seeking
recovery of a researcher’s patent profits, from patents involving the
patient’s genetic material . . . will likely recur.” 9 Furthermore, “[a]bsent
legislative intervention to compensate patients, they have reduced
incentives to donate their genetic material to further scientific research.” 10
The DNA collection from indigenous groups, however, has created a new,
much more ethically-charged, dialogue to this decade-old debate.

A. The Human Genome Diversity Project
¶5
The Human Genome Diversity Project (HGDP) served as the
catalyst behind the biological testing of indigenous groups. Founded by
Luigi Luca Cavalli-Sforza, a population geneticist at Stanford University,
and other U.S. scientists, the HGDP “aims to collect blood, skin, and hair
samples from hundreds of ethnic groups around the world and use new
techniques to preserve genetic information indefinitely.” 11 The HGDP is
part of an international movement that wishes to “analyz[e] the structure of
human DNA and ascertain[] the location of all human genes by mapping
and sequencing the human genome.” 12 Collection of this information is of
utmost importance to scientists for the following reasons:

First, thus far the vast majority of detailed research into human
genetics has been done with Europeans or North Americans of
European descent, and thus omits the eighty percent of the world’s
population that is not of European ancestry. It is fundamentally unfair
to the majority of humanity to describe the human genome without
7

See, e.g., Moore v. Regents of Univ. of Cal., 793 P.2d 479 (Cal. 1990), cert.
denied, 499 U.S. 936 (1991).
8
Greenberg v. Miami Children’s Hospital, 264 F. Supp. 2d 1064, 1067-68 (S.D.
Fla. 2003).
9
Eric Chen, Who Owns the Property Rights to Your Genetic Material, 13 U.
BALT. INTELL. PROP. L.J. 1, 2 (2004) (discussing recent state and federal judicial
patterns concerning the granting of property rights in human tissue).
10
Id.
11
DARRELL A. POSEY & GRAHAM DUTFIELD, BEYOND INTELLECTUAL
PROPERTY: TOWARD TRADITIONAL RESOURCE RIGHTS FOR INDIGENOUS PEOPLES
AND LOCAL COMMUNITIES APP. 1 at 161 (International Development Research
Centre 1996), available at http://www.idrc.ca/openebooks/799-x/#page_16.
12
Gargano, supra note 2, at 5 (critiquing the U.S. patent system because it
“does not treat patent applications on human genome sequences any differently
than it treats patent applications claiming chemical compositions of matter”).
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including a representative sample of all humans. Second, studying
human genetic diversity will help us understand better the workings of
evolution in humans, including the ways in which culture influences
evolution. Third, greater knowledge of human genetic diversity will
improve medicine, both because it will advance the study of those
genetic diseases found largely in non-European populations, and
because genetic variation is basic to better understanding a host of
diseases found in all peoples. Finally, studying human diversity will
help us uncover our shared human history. Genetic results, when
interpreted along with evidence from anthropology, archaeology,
history, linguistics, and other fields, will help map human migrations
and expansions in prehistoric times. 13
¶6
HGDP advocates also point out that ethnic groups that in the past
have been subjects of genetic testing have welcomed the research. In
particular, the Old Order Amish were very concerned about mental health
issues within their ethnic group and were thus very cooperative with genetic
researchers. 14 Like indigenous populations, “this group is located within a
small geographic location” and “is both genetically and culturally
homogenous.” 15 The HGDP advocates that participation from all groups is
essential because “[r]esearch in human genetics is by its nature collective
research. One person’s genome is only revealing in the context of the
genomes of others.” 16 The individual, the group, and the world all benefit
from this information. For instance:

Research into a family or a group of families with a high incidence of
a disease may reveal that those families are more likely than average to
carry a "flawed" allele of a gene. That information necessarily has
implications for every family member, whether she took part in the
research or not. She knows that she, her parents, her children, and her
other relatives are at a higher risk for this genetic disorder. She will
often learn that she can be tested for the disease allele—and so will
everyone else, including her potential employers and insurers. The
same dynamic is at work in ethnic groups. The fact that sickle cell
anemia, for example, is much more common among AfricanAmericans than among European-Americans necessarily provides
some probabilistic information about African-Americans who did not

13

Henry T. Greely, Symposium: International Health Law, The Control of
Genetic Research: Involving the “Groups Between,” 33 HOUS. L. REV. 1397,
1414–15 (1997).
14
Id. at 1409.
15
Id.
16
Id. at 1409-10.
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take part in the genetic tests. Information about groups has
implications for all the members of those groups. 17

B. Indigenous Peoples
Indigenous populations have seen the seemingly commendable
goals of the HGDP in a different light. Although the project’s goals suggest
that “hundreds of ethnic groups” will be tested, the result has been that
“peoples to be investigated are very small indigenous groups chosen in part
because of their endangered situation.” 18 Many groups view the project as a
new type of “biocolonialism.” 19 Isolated indigenous groups have become
an ever-limited and rare “source” for the research community. 20 Members
of indigenous groups loathe this characterization and feel exploited for their
biological resources, recognizing that “the presence of company scientists
on medical teams—drawing blood as they provided services—represented
the growing corporate interest in their genes.” 21
¶7

¶8
Indigenous groups also resent that their tribes have yet to reap any
benefit for such invasive testing and have begun to “demand equitable
compensation.” 22 Equitable compensation could be given in the simplest
form, such as money, or it could just mean that the results of the testing
benefit the community from which samples were taken. However, neither of
these forms of compensation is being used. This is largely due to the fact
that the original goals of the HGDP were indifferent to benefiting the
subjects of the test. The HGDP began its research with a purely scientific
focus, stating that “[t]he purpose of the research is ultimately to add to the
body of scientific knowledge without focusing on the needs of a specific
community.” 23 The subjects of the tests are only considered “necessary to
provide data, and [are] rarely involved in the research development.” 24
Biomedical results were not meant to be used for, or returned to, the

17

Id. at 1411.
POSEY & DUTFIELD, supra note 11, at 161.
19
Dorothy Nelkin, Symposium: Legal and Ethical Issues in Genetic Research on
Indigenous Populations, A Brief History of the Political Work of Genetics, 42
JURIMETRICS J. 121, 127 (2002).
20
Laura S. Underkuffler, Human Genetic Studies: The Case for Group Rights,
J.L. MED. & ETHICS (forthcoming Spring 2006) (manuscript at 11, on file with
author).
21
Nelkin, supra note 19, at 127.
22
Id.
23
Laura Arbour & Doris Cook, DNA on Loan: Issues to Consider when
Carrying out Genetic Research with Aboriginal Families and Communities,
COMMUNITY GENETICS 3 Vol. 319, (2006), available at
https://courses.washington.edu/phg580/readings/CMG319%252Epdf.pdf.
24
Id.
18
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participants. 25 In fact, the individual subjects who participated in the
research were kept anonymous. 26
¶9
Finally, there is concern as to whether indigenous populations, as
groups, have any rights or liberties at all to stand against the biological
testing being conducted. Under American jurisprudence, group rights “are
generally ignored.” 27 The genetic testing of indigenous groups, however,
raises many group issues because the results of the tests often present very
specific information about the “ill health” of the entire tribe, which can
cause panic and fear within the group, as well as bestow upon the entire
group a certain “stigmatization” that can lead to “discrimination by third
parties, who act on the prejudices and predictions that this information may
arouse.” 28 Also, many of these groups believe that their genetic materials
“hold traditional and spiritual significance.” 29 A Native American
geneticist, Dr. Frank Dukapoo, has stated that “[f]or an Indian, it’s not just
DNA, it’s part of a person, it is sacred, with deep religious significance. It is
part of the essence of a person.” 30

This opposition was not anticipated by HGDP scientists. 31
Researchers never foresaw that their work, which they believed would
benefit everyone in the world in some sense, would raise such ethical issues.
Although researchers stated that the HGDP would be carried out in the
general “interests” of indigenous peoples (i.e. it would “immortalize
vanishing peoples”), it appears as though those “interests” had nothing to do
with the actual desires of the research subjects. 32 Furthermore, “[t]he
research became a lightning rod for broader concerns about the exploitation
of developing countries and their resources.” 33 The scientific goals of the
HGDP have been muddled with ethically-loaded questions such as whether
“the blood taken for this research [was] intended for the purpose of
improving health or for the purpose of patents and profits.” 34 HGDP
scientists have lost sight of the deeper implications of their work, and
¶10

25

Id.
Id.
27
Underkuffler, supra note 20, at 6 (noting that “whether we are speaking of
private wrongs or wrongs by the government, it is generally assumed…that it is
the individual who is the focus of concern”).
28
Underkuffler, supra note 20, at 19.
29
Arbour & Cook, supra note 23, at 3.
30
Id. at 3 (quoting Indigenous People, Genes and Genetics: What Indigenous
People Should Know about Biocolonialism. A Primer and Resource Guide.
Nevada, Indigenous Peoples Council on Biocolonialism (2000), available at
http://www.ipcb.org/publications/primers/index.html.
31
Nelkin, supra note 19, at 128.
32
Id.
33
Id.
34
Id.
26
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“critics believe the research [is] only exploiting indigenous people,
intervening in their heritage, families, communities, and nations.” 35

II. INTELLECTUAL PROPERTY OVER DATA COLLECTED
¶11
The USPTO, despite the erupting public controversy, has actually
encouraged “patents on newly discovered, naturally occurring genes, DNA
fragments, proteins, and other biochemicals in contravention of long
established principles of patent law.” 36 The USPTO’s Director of
Biotechnology Examination, John Doll, declared that genetic and DNA
sequencing should be patented for the following reasons:

Without the incentive of patents, there would be less investment in
DNA research, and scientists might not disclose their new DNA
products to the public. Issuance of patents to such products not only
results in the dissemination of technological information to the
scientific community for use as a basis for further research, but also
stimulates investment in the research, development, and
commercialization of new biologics. It is only with the patenting of
DNA technology that some companies, particularly small ones, can
raise sufficient venture capital to bring beneficial products to the
marketplace or fund further research. A strong U.S. patent system is
critical for the continued development and dissemination to the public
of information on DNA sequence elements. 37
¶12
Critics of this approach, however, demand “an explanation as to
how chemicals found in the human body can be ‘inventions’ under the
positive law of patents.” 38 Clearly a patent application involving the human
body varies greatly from, say, patent applications involving software or an
electronic device. Currently, however, the USPTO does not demand
separate patent application requirements.
¶13
Two U.S. patents, in particular, shed light on the need for
government involvement in curbing patent applications. The first effort to
patent the genetic sequences revealed from the testing of indigenous groups
was the Guayami patent. A Guayami woman, who belongs to an indigenous
group in Panama, was said to have been “illiterate and unschooled” yet

35

Id.
Linda J. Demaine & Aaron X. Fellmeth, Reinventing the Double Helix: A
Novel and Nonobvious Reconceptualization of the Biotechnology Patent, 55
STAN. L. REV. 303, 304-05 (2002) (critiquing how the USPTO has started a
spreading trend in “acclaiming the patentability of naturally occurring
biochemicals after ‘isolation and purification’”).
37
Id. at 304-05 (citing John J. Doll, The Patenting of DNA, 280 SCIENCE 689
(1998)).
38
Id. at 305.
36
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allegedly gave “‘informed oral consent’ to the research, even though neither
the tribe nor the woman knew anything about the development of the cell
line or the patent application.” 39 This patent application was “filed on
behalf of the Department of Commerce, published as PCT application
WO92/08784 on May 29, 1992 and directed to ‘Human T-Lymphotropic
Virus Type II from Guayami Indians in Panama.’” 40
¶14
As a result of the patent application, the President of the Guayami
General Congress wrote a letter to the U.S. Secretary of Commerce. 41 First,
the letter “demand[ed] that the application be withdrawn because it had
been made without consultation with the Guayami community or its
traditional organizations.” 42 Second, the letter asserted that “this is not an
invention but rather a discovery of an antibody which is part of the blood of
a Guayami woman.” 43 The letter also queried what, if any, benefits the
Guayami people would gain from the proposed patent application. 44 As a
result of this protest from the Guayami leadership as well as from the Rural
Advancement Foundation International (RAFI) and numerous public
interest groups, the patent was withdrawn. 45
¶15
The United Nations (UN) also responded to the Guayami patent
with a “Draft Declaration on the Rights of Indigenous Peoples . . . including
human genetic materials as cultural property that indigenous populations are
entitled to control.” 46 The UN supported a view, as taken up by many
protestors, that individuals should have property rights in their biological
material and should not be forced to comply with the whims of researchers
when it comes to the human body. 47
¶16
In response to, and slightly rejecting, the UN’s stance that
indigenous people should have control over their genetic material, Henry
39

David E. Winickoff, Governing Population Genomics: Law, Bioethics, and
Biopolitics in Three Case Studies, 43 JURIMETRICS J. 187, 200 (2003).
(examining three case studies as exemplary of changes in population genomics,
including “the Human Genome Diversity Project, Iceland’s Health Sector
Database, and ‘Clinical Genomics’ as defined by the Beth Israel-Ardais
collaboration”).
40
Kate H. Murashige, Patent Protection for Biotechnology, 382 PLI/PAT 473,
476 (1994) (commenting on the environmental and socioeconomic impact of
biotechnology “inventions”/patents).
41
Id.
42
Id.
43
Id. (quoting the actual letter).
44
Id.
45
Id. See also Alternative Law Forum—TRIPS, Indigenous Knowledge and the
Bio-rush, http://altlawforum.org/PUBLICATIONS/document.2004-1218.1352831511 (last visited May 11, 2006).
46
Demaine & Fellmeth, supra note 36, at 438.
47
Id.
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Greely, a Stanford Law professor as well as chair of an ethics subcommittee
for HGDP, protested that “the idea that the U.S. government owns the
person or his genetic material is absolute rubbish . . . . [T]he donors
involved can continue, obviously, to use their own DNA to run their
bodies.” 48 Greely believes that once separated from the body, the genetic
material of indigenous people no longer shares a relationship with the body
that it was taken from. This view does not assuage concerns regarding the
“prevalent popular belief that ownership of another person’s genetic
material invades that person’s privacy; violates his or her bodily integrity,
often for purposes of economic exploitation; and offends his or her human
dignity.” 49
¶17
The second controversial claim for intellectual property over an
indigenous person’s biological material concerns the Hagahai 50 patent.
Here, biomedical researchers successfully “patented the T-lymphotrophic
virus found in blood of the Hagahai people in Papua New Guinea, believing
that it could be developed into a diagnostic tool or vaccine for certain types
of leukemia.” 51 The scientists who filed the Hagahai patent claimed to have
“negotiated a profit-sharing agreement with the Hagahai, a tribe that had
had no contact with outsiders until 1984, when some tribe members sought
help for an illness that afflicted the group.” 52 Public interest groups were
outraged. RAFI described the incident as an egregious act of “biopiracy”
and human “bioprospecting.” 53
¶18
Despite the public outcry, the USPTO granted the application for
the Hagahai patent to the National Institute of Health (NIH). The patent
application apparently met the congressionally established “invention”
requirement. 54 The patent application read as follows:
48

Id.
Id.
50
Patricia A. Lacy, Gene Patenting: Universal Heritage vs. Reward for Human
Effort, 77 OR. L. REV. 783, 794–95 (1998) (“The Hagahai are a 260-member,
hunter-horticulturist group which first made sustained contact with government
and missionary workers in 1984. The Hagahai are of particular interest to the
NIH because tribe members carry the gene that predisposes humans to leukemia,
yet they do not manifest symptoms of the illness.”)
51
Winickoff, supra note 39, at 201.
52
Id.
53
Id.
54
Lacy, supra note 50, at 796 (“The U.S. Constitution establishes the basis for
protecting invention in the United States: ‘To promote the Progress of Science
and useful Arts, by securing for limited Times to Authors and Inventors the
exclusive Right to their respective Writings and Discoveries.’ Patent law has
interpreted the framers’ use of ‘Discoveries’ to refer to ‘invention,’ as in
discoveries requiring human innovation. More recently, biotechnology has
blurred the distinction between ‘discovery’ and ‘invention.’”)
49
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[T]he present invention relates to a vaccine for humans against
infection with and diseases caused by HTLV-I (Human TLymphotropic Virus) and related viruses comprising a non-infectious
antigenic portion of the PNG-1 variant, in an amount sufficient to
induce immunity against said infection and disease, and a
pharmaceutically acceptable carrier. 55
¶19
It appears as though biological material taken from human beings
can, in fact, constitute a patentable invention. In fact, the Supreme Court
laid out the lax test for patenting biological material in Diamond v.
Chakrabarty 56 where the majority supported the notion that “anything under
the sun that is made by man” constitutes patentable subject matter as long as
there is a “human-made aspect” to it. 57 In the end, the Hagahai patent
produced little financial award for its owners, and the rights to the patent
were abandoned. 58

III. THE RESPONSIBILITIES OF THE U.S. PATENT OFFICE
Although the patenting of biological resources has existed for the
last ten years, the USPTO has failed to modify how it reviews patents
involving genetic resources. Scholars currently believe there is virtually no
review at all. 59 U.S. Senator Mark O. Hatfield has voiced his concern for
such inaction, noting that “the underlying ethical decisions related to the
developments in biomedicine transcend our . . . patent laws,” and not only
do they transcend our patent laws, but “they transcend our national
borders,” as is the case with the biological research of indigenous peoples. 60
Researchers are rushing to patent human genome sequences. Consider the
fact that on just one day “the National Institute of Health (NIH) filed patent
applications on 2300 gene fragments,” which is surprising considering that
“the Patent and Trademark Office (PTO), aided only by centuries old patent
law, could offer such protection.” 61 One would think that the patenting of
genetic material extracted from human beings “is more than a technical or
legal question of patentability.” 62 To date, it looks like the USPTO has
failed to implement any type of formal ethical review process of patent
applications. The floodgates remain open for patent application regarding
¶20

55

Lacy, supra note 50, at 794 (quoting U.S. Patent No. 5,397,696 (filed Aug. 12,
1991).
56
447 U.S. 303.
57
Id. at 309 n.3.
58
Winickoff, supra note 39, at 200.
59
Email from Arti Rai, Professor of Law, Duke University School of Law (Feb.
7, 2006) (on file with author).
60
Mark O. Hatfield, From Microbe to Man, 1 ANIMAL L. 5, 6 (1995).
61
Id.
62
Id.
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genes from the human body. As a result of this failure, Senator Hatfield
advocated the following to Congress:
The USPTO has no way of dealing with the various moral,
international, economic and environmental questions which arise from
the patenting of human genes, cells, and organs, or the patenting of
genetically engineered animals. Careful consideration and examination
has not taken place in the case of the genetic alteration and patenting
of human genes and body parts, or in the case of the creation and
patenting of transgenic animals. In each session of Congress since
1987, I have introduced legislation to place a moratorium on allowing
the Patent and Trademark Office to issue patents on living
organisms. 63
¶21
Some groups, however, are taking action, including the HGDP. In
response to the public dismay at the Hagahai and Guayami patent
applications, the North American Regional Committee of the Diversity
Project of the HGDP developed a “Proposed Model Ethical Protocol (MEP)
For Collecting DNA Samples.” 64 Although nothing like this has been
implemented by the USPTO, the HGDP’s own efforts have helped to curb
patent applications in the U.S. and address some of the ethical issues at
stake. The MEP has inserted a new ideology into their work, stating that
“the research must ‘not only [do] no harm to the participating communities,
but, where possible, bring them benefits.’” 65 This has been a shift from
what much of the public considered as a dispassionate view on research
subjects. Further, the MEP states that the HGDP itself “‘will not profit from
any commercial uses of samples it gathers or knowledge derived from those
samples’ and that the HGDP ‘has vowed to ensure that, should commercial
products be developed as a result of the HGDP’s collections, a fair share of
the financial rewards shall return to the sampled populations.’” 66 Dr. David
E. Winickoff suggests three possible ways in which these requirements can
be satisfied as set out by the Protocol:

(1) researchers could not “make use of the HGDP’s samples or data in
a patent application or a commercial product without the express
written permission of the sampled populations involved, . . subject to
whatever conditions they impose for that permission;” (2) “anyone
making commercial use of the HGDP’s samples would pay a set
percentage royalty . . . for the benefit of the sampled populations;” and
(3) “anyone making commercial use of the HGDP’s samples or data
63

Id.
Winickoff, supra note 39, at 197.
65
Id. at 200 (quoting Symposium, Proposed Model Ethical Protocol for
Collecting DNA Samples, 33 HOUS. L. REV. 1431, 1436 (1997)).
66
Id. at 200-01 (quoting Symposium, Proposed Model Ethical Protocol for
Collecting DNA Samples, 33 HOUS. L. REV. 1431, 1466-67 (1997)).
64
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would have to negotiate a reasonable financial payment with a trustee
for the sampled populations, with the proceeds for the population’s
benefit." 67
¶22
Although the HGDP has not vowed to stop its research altogether, it
does aim to “stick to science”—that is, it is making it clear that it is not in it
for its profit potential. However, this MEP does not rule out commercial
uses of the research. In essence, the HGDP is trying to rid itself of the moral
implications of profiting from collected biological material. This act
essentially places an even greater responsibility on the USPTO. With the
HGDP’s MEP washing its hands clean of the possible uses of its research,
the USPTO now stands even more alone as a potential barrier to patents
involving the genetic materials of indigenous peoples. In its MEP, the
HGDP also agrees that if profits do result from the research that it will
attempt to return some of those financial gains to indigenous groups. This
MEP, however, does not come close to addressing some of the “property”
issues at stake (i.e. is there a property interest either individually or
collectively in human genetic material at all?). Nor does it consider the
sacred value that many indigenous groups place on the biological matter
which is being taken from them.
¶23
The USPTO has yet to implement its own Model Ethical Protocol
or any procedure of “ethical review.” 68 One scholar, Nuno Pires de
Carvalho, proposed a rather novel “re-engineering” of the law concerning
biotechnology patents. 69 In particular, he suggests that the government
should implement, as a requisite for patentability, the “requirement that
applicants for patents in the field of biotechnology disclose the source of the
genetic resources eventually used as raw materials or tools in the inventive
activity” 70 (“Carvalho Requirement”). He also suggests that evidence, if
any, of informed consent from the research subjects be included in the
application. 71 However, what should constitute proper informed consent
and how scientists should go about getting it is still very controversial. 72
¶24
The Carvalho Requirement has already been integrated into two
foreign statutes: “Andean Decision No. 391 of August 16, 1996, which
67

Id.
Rai, supra note 59.
69
Nuno Pires de Carvalho, Requiring Disclosure of the Origin of Genetic
Resources and Prior Informed Consent in Patent Applications without
Infringing the TRIPS Agreement: The Problem and the Solution, 2 WASH. U.
J.L. & POL’Y 371 (2000).
70
Id. at 374.
71
Id.
72
Winickoff, supra note 39, at 197 (discussing recent “innovations in informed
consent” such as the use of “group consent” and accompanying criticism of such
novel uses).
68
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establishes a Common Regime on Access to Genetic Resources; and the
Biodiversity Law (No. 7788) of Costa Rica enacted May 27, 1998.” 73 Both
of these laws require patent applicants to describe, in detail, the following:
“information concerning the origin of the genetic resource in question and
some proof of prior informed consent from government authorities as well
as traditional knowledge holders, whenever the resource will be obtained
through their technical knowledge.” 74 Furthermore, the Carvalho
Requirement is expected to be proposed to the World Trade Organization
(WTO) and the World Intellectual Property Organization (WIPO), and there
has already been a proposed amendment to Article 29 of the TRIPS
Agreement. 75
¶25
It appears as though the international community has started to
recognize the lack of oversight in biological patents. For instance, when the
WIPO Standing Committee on the Law of Patents convened in 1999,
Colombia proposed some very ethically-conscious language to be included
in the proposed Patent Law Treaty:

1. All industrial property protection shall guarantee the protection of
the country’s biological and genetic heritage. Consequently, the grant
of patents or registrations that relate to elements of that heritage shall
be subject to their having been acquired legally.
2. Every document shall specify the registration number of the contract
affording access to genetic resources and a copy thereof where the
goods or services for which protection is sought have been
manufactured or developed from genetic resources, or products
thereof, of which one of the member countries is the country of
origin. 76

Carvalho considers the Colombian proposal to be a more
“substantive” requirement than his proposal in that the Carvalho
Requirement “concerns information that does not relate directly to the
activity of inventing” and it “does not characterize the invention itself.” 77
Rather, he refers to the Carvalho Requirement as an “accessory” not unlike
other requirements found within a patent application such as “where the
invention was invented as part of the work performed under a contract with
the government” and the applicant must provide “any document containing
a statement which indicates any government licensing rights in the
¶26

73

Carvalho, supra note 69, at 375-76 (citing Common Regime on Access to
Genetic Resources, Andean Decision No. 391, Andean Community of Nations
(July 2, 1996); Article 81 of the Biodiversity Law of Costa Rica).
74
Carvalho, supra note 69, at 376.
75
Id. at 376-77.
76
Id. at 377.
77
Id. at 377-78.
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invention and identifies the government contract.” 78 What both the
Carvalho Requirement and the Colombian proposal share in common,
however, is that each impose a “condition on patentability.” 79 And as with
any imposed condition, both of these proposals would make it more
challenging for researchers to assert intellectual property rights over
biological material collected from indigenous populations.

IV. CONCLUSION
¶27
With the advent of a heightened international consciousness
concerning the ethical implications of collecting the DNA of indigenous
peoples, it would seem as though the USPTO would have taken some sort
of step by now to modify the patent application process. Unfortunately, no
changes have been made. Rather, the USPTO has approved of what some
see as a “patent on a foreign citizen.” 80 This iBrief, by outlining the multifaceted debate on this issue as well as by demonstrating how other countries
have chosen to revise their patent application process, hopes to increase
public awareness and contribute to the patent reform movement concerning
human biological material.

The above proposals offer some guidance as to how the U.S. might
finally implement a procedure of ethical review when faced with biological
patents. Even minimal “accessory” changes to the U.S. patent application
would create a heightened system of awareness as to the activities being
conducted behind the veil of the patent application. Also, they put a burden
on the patent applicant herself. Hopefully, the USPTO can start to move
towards a more active role in curbing ethically-questionable patent
applications, so that not “anything under the sun that is made by man” 81 is
patentable, especially when it involves the sacred genetic elements that
many indigenous groups believe make up the essence of who they are as
people.
¶28
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Id. at 378.
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Indigenous Person from Papua New Guinea claimed in US Government
Patent, Oct. 4, 1995, http://www.spunk.org/texts/colon/sp001144.txt.
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Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
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